- Home
- UNCY vs BTAI Comparison
UNCY vs BTAI Comparison
Compare UNCY & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- BTAI
- Stock Information
- Founded
- UNCY 2016
- BTAI 2017
- Country
- UNCY United States
- BTAI United States
- Employees
- UNCY N/A
- BTAI N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- UNCY Health Care
- BTAI Health Care
- Exchange
- UNCY Nasdaq
- BTAI Nasdaq
- Market Cap
- UNCY 31.9M
- BTAI 28.7M
- IPO Year
- UNCY 2021
- BTAI 2018
- Fundamental
- Price
- UNCY $0.46
- BTAI $0.57
- Analyst Decision
- UNCY Strong Buy
- BTAI Strong Buy
- Analyst Count
- UNCY 4
- BTAI 4
- Target Price
- UNCY $5.50
- BTAI $5.00
- AVG Volume (30 Days)
- UNCY 1.9M
- BTAI 458.6K
- Earning Date
- UNCY 11-13-2024
- BTAI 11-14-2024
- Dividend Yield
- UNCY N/A
- BTAI N/A
- EPS Growth
- UNCY N/A
- BTAI N/A
- EPS
- UNCY N/A
- BTAI N/A
- Revenue
- UNCY N/A
- BTAI $2,276,000.00
- Revenue This Year
- UNCY N/A
- BTAI $247.03
- Revenue Next Year
- UNCY N/A
- BTAI $88.16
- P/E Ratio
- UNCY N/A
- BTAI N/A
- Revenue Growth
- UNCY N/A
- BTAI 83.25
- 52 Week Low
- UNCY $0.20
- BTAI $0.50
- 52 Week High
- UNCY $1.82
- BTAI $4.32
- Technical
- Relative Strength Index (RSI)
- UNCY 48.64
- BTAI 43.77
- Support Level
- UNCY $0.41
- BTAI $0.50
- Resistance Level
- UNCY $0.55
- BTAI $0.72
- Average True Range (ATR)
- UNCY 0.06
- BTAI 0.08
- MACD
- UNCY -0.01
- BTAI -0.01
- Stochastic Oscillator
- UNCY 23.47
- BTAI 20.70
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.